Abstract
We conducted a prospective analysis of somatostatin receptor scintigraphy using 111In radiolabeled pentetreotide, a somatostatin analog, in patients with breast cancer in the aim to visualize the primary tumor and axillary or parasternal metastatic extension because some malignant breast tumors express somatostatin receptors (SS-R) in 50%, approximately. An analysis of SS-R was performed by autoradiography.
Patients and methods.Thirteen patients with clinically suspected breast tumors (T1, T2), and at least one palpable axillary node (N1) were included. In vivo planar scintigrams were acquired 1, 4, and 24 h after subcutaneous, then after intravenous injections (24 h delay between injections). Improved 111In-pentetreotide uptake in invaded nodes after subcutaneous injection was hypothesized. Ex vivo scintigrams of surgical specimens were also acquired immediately after tumor resection and axillary dissection. Pathological examination and receptor autoradiography were performed on all surgical specimens.
Results.Among 11 pathologically proven malignant tumors (9 ductal and 2 lobular carcinomas), only four were scintigraphically visible although six expressed SS-R receptors in vitro. Among six pathologically proven malignant nodes, four expressed SS-R, including two visualized scintigraphically. Scintigrams acquired after subcutaneous injections were less sensitive than after intravenous injections. There were no false positive. False negatives occurred in cases with small tumors with low-density or heterogeneously distributed SS-R. There was no significant difference by histological type or prognostic factors.
Conclusion.Somatostatin receptor scintigraphy does not appear to be sensitive enough to evaluate axillary node extension of breast cancer or even to confirm the presence of tumoral tissue, and this whatever the administration route for 111In-pentetreotide.
Similar content being viewed by others
References
Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER: Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer 52: 1551–1557, 1983
Kissin MW, Querci della Rovere G, Easton D, Westbuy G: Risk of lymphoedema following the treatment of breast cancer. Br J Surg 73: 580–584, 1986
Hoe AL, Iven D, Royle GT, Taylor I: Incidence of arm swelling following axillary clearance for breast cancer. Br J Surg 79: 261–262, 1992
Fekete M, Wittiliff JL, Schally AV: Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormonereleasing hormone, somatostatin, epidemal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. Clin Lab Anal 3: 137–147, 1989
Reubi JC, Waser B, Foekens JA, Klijn JGM, Lamberts SWJ, Laissue J: Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: relationship to EGF-receptors. Int J Cancer 46: 416–420, 1990
Reubi JC, Kvols LK, Waser B, et al.: Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 50: 5969–5977, 1990
Reubi JC, Mazzucchelli L, Laissue J: Intestinal vessels express a high density of somatostatin receptors in human in-flammatory bowel disease. Gastroenterology 106: 951–959, 1994
Viki-Topic S, Raisch KP, Kvols LK, Vuk-Pavlovic L: Expression of somatostain receptor subtypes in breast carcinoma, carcinoid tumor, and renal cell carcinoma. J Clin Endocrinol Metab 80: 2974–2979, 1995
Reubi JC, Torhorst J: The relationship between somatostatin, epidermal growth factor, and steroid hormone receptors in breast cancer. Cancer 64: 1254–1260, 1989
Bajc M, Ingvar C, Palmer J: Dynamic Indium-111-pentetreotide scintigraphy in breast cancer. J Nucl Med 37: 622–626, 1996
Van Eijck CHJ, Krenning EP, Bootsma A, et al.: Somatostatin receptor scintigraphy in primary breast cancer. Lancet 343: 640–644, 1994
Krenning EP, Kwekkeboom DJ, Bakker WH, et al.: Somatostatin receptor scintigraphy with [Indium-111-DTPA-DPhe-1] and [iodine-123-Tyr-3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20: 716–731, 1993
Foekens JA, Portengen H, van Putten WLJ, et al.: Prognostic value of receptors for insulin-like growth factor 1, somatostatin and epidermic growth factor in human breast cancer. Cancer Res 49: 7002–7009, 1989
Vural G, Atasever MUT, Ozur I, Ozdemir A, Gokcora N: Comparison of indium-111 octreotide and thallium-201 scintigraphy in patients mammographically suspected of having breast cancer: preliminary results. Eur J Nucl Med 24: 312–315, 1997
Chiti A, Agresti R, Maffioli LS, et al.: Breast cancer staging using technetium-99m sestamibi and indium-111 pentetreotide single-photon emission tomography. Eur J Nucl Med 24: 192–196, 1997
Cimitan M, Volpe R, Candiani E, et al.: The use of thallium-201 in the preoperative detection of breast cancer: an adjuct to mammography and ultrasonography. Eur J Nucl Med 22: 1110–1117, 1995
Lee VW, Sax EJ, McAneny DB, et al.: A complementary role for thallium-201 scintigraphy with manmmography in the diagnosis of breast cancer. J Nucl Med 34: 2095–2100, 1993
Waxman AD, Ramanna L, Memsic LD, et al.: Thallium scintigraphy in the evaluation of mass abnormalities of the breast. J Nucl Med 34: 18–23, 1993
Burak Z, Argon M, Memis A, et al.: Evaluation of palpable breast masses with 99mTc-MIBI: a comparative study with mammography and ultrasonography. Nucl Med Comm 15: 604–612, 1994
Campeau RJ, Kronemer KA, Sutherland CM: Concordant uptake of Tc–99m sestamibi and T1-201 in unsuspected breast tumor. Clin Nucl Med 12: 936–937, 1992
Kao CH, Wang SJ, Liu TJ: The use of technetium-99m methoxyisobutylisonitrile breast scintigraphy to evaluate palpable breast masses. Eur J Nucl Med 21: 432–436, 1994
Khalkhali I, Cutrone JA, Mena I, et al.: Scintimammography: the complementary role of Tc-99m sestamibi prone breast imaging for the diagnosis of breast carcinoma. Radiology 196: 421–426, 1995
Scopinaro F, Schillaci O, Scarpini M, et al.: Technetium-99m sestamibi: an indicator of breast cancer invasiveness. Eur J Nucl Med 21: 984–987, 1994
Dehdashti F, Mortimer JE, Siegel BA, et al.: Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro assays. J Nucl Med 36: 1766–1774, 1995
Adler LP, Crowe JP, Al-Kaisi NK, Sunshine JL: Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology 187: 743–750, 1993
Kubota K, Matsuzawa T, Amemiya A, Kondo M, Fujiwara T, Watanuki S: Imaging of breast cancer with [18F]fluorodexyglucose and positron emission tomography. J Comput Assist Tomogr 13: 1097–1098, 1989
Nieweg OE, Kim EE, Wong WH, et al.: Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 71: 3920–3925, 1993
Tse NY, Hoh C, Hawkins RA, et al.: The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 216: 27–34, 1992
Wahl RL, Cody RL, Hutchins GD, MudgeTT EE: Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 179: 765–770, 1991
Minn H, Soini I: [18F]Fluorodeoxyglucose scintigraphy in diagnosis and follow-up of treatment in advanced breast cancer. Eur J Nucl Med 15: 61–66, 1989
Huovinen R, Leskinen-Kallio S, Nagren K, Lehikoinen P, Ruotsalainen U, Teräs M: Carbon-11-methionine and PET in evaluation of treatment response of breast cancer. Br J Cancer 67: 787–791, 1993
Rights and permissions
About this article
Cite this article
Albérini, J.L., Meunier, B., Denzler, B. et al. Somatostatin receptor in breast cancer and axillary nodes: study with scintigraphy, histopathology and receptor autoradiography. Breast Cancer Res Treat 61, 21–32 (2000). https://doi.org/10.1023/A:1006447325077
Issue Date:
DOI: https://doi.org/10.1023/A:1006447325077